Table 2.
Characteristics at the Time of Cinacalcet initiation in Chronic Kidney Disease Patients, Stockholm, Sweden 2006–2012.
| At Cinacalcet initiation (n = 435) | ||
|---|---|---|
| Timing of cinacalcet initiation | Months after baseline, mean (SD) | 22.8 (17.0) |
| Comorbidity before initiation | Charlson comorbidity index | 3.68 (1.9) |
| New fracture before cinacalcet initiation | 18 (4.1) | |
| New cardiovascular event before cinacalcet initiation | 76 (17.5) | |
| Laboratory values | Parathyroid hormone, median (IQR) | 636 (436–860) |
| P-Phosphate, median (IQR) | 1.8 (1.4–2.2) | |
| B-Haemoglobin | 119.5 (15.1) | |
| P-Albumin | 34.0 (4.3) | |
| P-Calcium, median (IQR) | 2.45 (2.28–2.59) | |
| Albuminuria (%) | ||
| none | 30 (12.0) | |
| micro | 43 (17.1) | |
| macro | 178 (70.9) | |
| Medication | Use of ACEi or ARB | 283 (65.1) |
| Use of Beta-blocker | 284 (65.3) | |
| Use of Vitamin D (active) | 316 (72.6) | |
| Use of Vitamin D supplement | 14 (3.2) | |
| Use of erythropoiesis stimulating agents | 212 (48.7) | |
| Use of Calcium supplement | 196 (45.1) | |
| Use of Phosphate binder | 316 (72.6) | |
| Use of Prednisolone | 100 (23.0) | |
| Renal replacement therapy (RRT) | No RRT | 109 (25.1) |
| Dialysis | 272 (62.5) | |
| Renal transplantation | 54 (12.4) |
The variables are presented as number (percentages) if categorical and median (interquartile range, IQR) or mean (Standard deviation, SD) if continuous. eGFR (glomerular filtration rate estimated by CKD-EPI equation) in ml/min/1.73 m2, ACEi (Angiotensin Converting Enzyme inhibitor), ARB (Angiotensin Receptor Blocker).